Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Background No approved therapies exist for neuromyelitis optica spectrum disorder
(NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes …
(NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes …
Hope for patients with neuromyelitis optica spectrum disorders—from mechanisms to trials
SJ Pittock, A Zekeridou, BG Weinshenker - Nature Reviews Neurology, 2021 - nature.com
Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory CNS disease that
primarily manifests as relapsing episodes of severe optic neuritis and myelitis. Diagnosis of …
primarily manifests as relapsing episodes of severe optic neuritis and myelitis. Diagnosis of …
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
A Traboulsee, BM Greenberg, JL Bennett… - The Lancet …, 2020 - thelancet.com
Background Satralizumab, a humanised monoclonal antibody targeting the interleukin-6
receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder …
receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder …
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking …
Background: Efficacy and safety of inebilizumab for treatment of neuromyelitis optica
spectrum disorder in adults seropositive for aquaporin-4 (AQP4)–immunoglobulin (Ig) G …
spectrum disorder in adults seropositive for aquaporin-4 (AQP4)–immunoglobulin (Ig) G …
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)–revised recommendations of the Neuromyelitis Optica Study Group …
T Kümpfel, K Giglhuber, O Aktas, I Ayzenberg… - Journal of …, 2024 - Springer
This manuscript presents practical recommendations for managing acute attacks and
implementing preventive immunotherapies for neuromyelitis optica spectrum disorders …
implementing preventive immunotherapies for neuromyelitis optica spectrum disorders …
[引用][C] International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
CT Tan - Neurology, 2016 - AAN Enterprises
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders |
Neurology Skip to main content Skip to main content AAN.com AAN Publications Author Center …
Neurology Skip to main content Skip to main content AAN.com AAN Publications Author Center …
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind …
JL Bennett, O Aktas, WA Rees, MA Smith, M Gunsior… - …, 2022 - thelancet.com
Background Inebilizumab is an anti-CD19 antibody approved for the treatment of
neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies …
neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies …
Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options
N Collongues, E Ayme-Dietrich, L Monassier… - Drugs, 2019 - Springer
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
nervous system. Although the prevalence of NMO is low, the rapid and severe impairment …
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
M Tahara, T Oeda, K Okada, T Kiriyama, K Ochi… - The Lancet …, 2020 - thelancet.com
Background Pharmacological prevention against relapses in patients with neuromyelitis
optica spectrum disorder (NMOSD) is developing rapidly. We aimed to investigate the safety …
optica spectrum disorder (NMOSD) is developing rapidly. We aimed to investigate the safety …
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects
SA Brod - Multiple Sclerosis and Related Disorders, 2020 - Elsevier
Importance Neuromyelitis optica (NMO-including NMO spectrum disorders [NMOSD]) is a
devastating disease. Eighty-three percent of patients with transverse myelitic (TM) attacks …
devastating disease. Eighty-three percent of patients with transverse myelitic (TM) attacks …